Shares of biotech contract research organizations are falling in Thursday trading after STAT News reported that the FDA is looking to lower the number of clinical trials required for drug approvals.
- Among movers: Charles River Laboratories -0.79%, ICON PLC -3.6%, Fortrea Holdings -6.1%, Medpace -5.5%, IQVIA Holdings -3.5%
- CROs provide research and development services to the pharmaceutical and biotechnology industry and often help in designing and running clinical trials
- FDA Commissioner
Marty Makary said the agency plans to begin requiring one clinical study, instead of the standard two, for medical products before consideration for approval, STAT News reported
To ...